Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
VistaGen Therapeutics
Biotech
Vistagen's social anxiety disorder asset stumbles in phase 3
The company still has one more key trial to read out in 2026 that could give its candidate a fighting chance at success.
Fraiser Kansteiner
Dec 17, 2025 2:44pm
Incyte, FDA, Sun Pharma and more—Chutes & Ladders
Jun 27, 2025 8:30am
Leaps by Bayer chief jumps to Bayer, too—Chutes & Ladders
Aug 25, 2023 9:30am
Vistagen stock soars 1,272% on social anxiety spray data
Aug 7, 2023 11:38am
VistaGen's social anxiety nasal spray finds open-label success
Mar 22, 2023 3:36pm
Vistagen pauses anxiety trial restart after seeing rivals fail
Feb 8, 2023 6:20am
